Nuvisan
Nuvisan is recorded as a service provider in 55 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 55 trials · Latest update first
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Efficacy and Safety of MBS2320 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study assessed 2 patients and treated 1 patient before termination.
- Delayed study start-up and slow patient recruitment prevented completion of planned enrollment on time.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
CONQUEST Platform Clinical Study for Conquering Scleroderma: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Study to Evaluate the Safety and Efficacy of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis
Sponsor Scleroderma Research Foundation
- Start (EU)
- Latest update
- Estimated end
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Sponsor Vaderis Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
(22615 SOHO-02) A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)
Sponsor Alvotech Swiss AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours
Sponsor Orion Corporation
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata
Sponsor Almirall S.A.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
Sponsor Recordati AG
- Start (EU)
- Latest update
- Estimated end
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
Sponsor Alvotech Swiss AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Premature termination prevented attainment of the planned sample size and substantially reduced follow-up, leaving very few evaluable participants at Week 52 and insufficient power for formal hypothesis testing.
These findings describe the trial, not the service provider’s performance or responsibility.
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
(22752) A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 in participants with metastatic or unresectable solid tumors with HER2-activating mutations
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors. (Master protocol)
Sponsor Bayer AG
- Start (EU)
- Latest update
- Estimated end
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
Sponsor ENYO Pharma
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Fifteen study centers were initiated, but 12 centers across the US, France, and Spain enrolled participants.
- The study enrolled 26 participants, exceeding the initially planned sample size of 20 to 24 participants.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy
Sponsor Rycarma Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter phase 1/2 dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas
Sponsor OSE Immunotherapeutics
- Start (EU)
- Latest update
- Estimated end
- Not reported
EASi-HF Reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nuvisan?
The 2026-10-09 snapshot links Nuvisan to 55 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, Pharmacokinetics analysis, PK Analysis, among 22 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nuvisan?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Dermatology, Gastroenterology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nuvisan conducted?
The linked trials record locations in 25 countries, including Spain, Germany, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Nuvisan delivered services.
What can this page tell me about Nuvisan's trial experience?
Browse 55 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 4 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 3 recorded name variants under Nuvisan. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nuvisan France
- Nuvisan France S.A.R.L.
- Nuvisan GmbH